human cmv pp65-lamp mrna-pulsed autologous dcs
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2019 (NCT03688178)
Timeline
Indications
Studied for
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04963413 | Phase 1 | Dec 31, 2021 | Immunomic Therapeutics, Inc., University of Florida |
| NCT03927222 | Phase 2 | Jun 30, 2019 | Duke University |
| NCT03688178 | Phase 2 | Jan 31, 2019 | Duke University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Immunomic Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2021 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1